Paul A. Pham Pharm.D. and John G. Bartlett M.D.
Available formulation in Zambia: Powder for injection: 2 g (as hydrochloride) in vial.
- Generally reserved for the treatment of GC in PCN-allergic or pregnant patients.
- Gonorrhea (endocervical, urethral, and rectal): 2 gm IM x 1 dose
- Only 52% effective in treatment of pharyngeal GC.
Zambia Information Author: Paul A. Pham, Pharm. D.
- No longer available in the U.S.
- Gonorrhea (endocervical, urethral, and rectal)
|Trobicin||Spectinomycin||No longer available in the U.S. ||IM|
*Prices represent cost per unit specified and are representative of "Average Wholesale Price" (AWP).
AWP Prices were obtained and gathered by Lakshmi Vasist Pharm D using the Red Book, manufacturer's
information, and the McKesson database.
^Dosage is indicated in mg unless otherwise noted.
Gonorrhea (endocervical, urethral, and rectal): 2 gm IM x 1 dose (note: only 52% effective in the treatment of pharyngeal GC).
2 gm IM x 1.
2 gm IM x 1.
2 gm IM x 1, accumulation only occurs with repeated administration.
HD decrease dose by half, supplement or dose after HD.
No data;no supplemental needed. Consider 2 gm IM x1.
- Urticaria, transient rash and pruritus
- CNS: dizziness, headache, nervousness and insomnia
- GI: nausea and vomiting
- Increased ALT
Agent of choice for PCN-allergic pregnant patients or PCN-allergic patients who acquired GC in a fluoroquinolone-resistant endemic area (i.e., Asia, Hawaii and other Pacific Islands). Anyone treated with spectinomycin must be reevaluated 3-5 days after treatment if had pharyngeal exposure (only 52% effective at this site). No longer available in the U.S.